1. CARDIOVASCULAR DISEASE RISK FACTORS AND PREVENTION
=====================================================

In the latter half of the twentieth century, epidemiologic studies identified many important causes of cardiovascular disease (CVD) operating at the population and individual levels. Discovery of these "classical" risk factors (high blood pressure, dyslipidemia, smoking, diabetes, physical inactivity, and Western diet), along with the development of effective population-wide and high-risk prevention approaches to risk factors,^[@r01]^ contributed to a substantial decline in CVD mortality in many developed countries. Interest in CVD prevention has expanded in the United States to the extent that the American Heart Association (AHA) now promotes not only primary prevention of CVD through control of classical risk factors but also "primordial prevention" (ie, avoidance of ever having risk factors) and "maintenance of low risk" (ie, maintaining optimal risk factor levels throughout life).^[@r02]^

2. PREDICTION OF CARDIOVASCULAR RISK IN INDIVIDUALS
===================================================

Risk prediction equations derived from epidemiologic cohort studies have proved to be useful tools in primary prevention of CVD at the individual, clinical level.^[@r03],[@r04]^ The Framingham equation for estimating 10-year risk of coronary heart disease (CHD) is the most widely used risk prediction model,^[@r05]^ although others exist.^[@r06]--[@r09]^ The Framingham model is based on the classical risk factors, namely, age, sex, blood pressure, low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol, smoking, and sometimes diabetes. Clinical assessment of estimated 10-year CHD risk is promoted in order to guide hyperlipidemia treatment in the United States.^[@r10]^ Furthermore, the AHA recommends that for the purpose of CHD prevention clinicians should measure risk factors and calculate overall CHD risk in all adult patients.^[@r11]^ However, use of CHD risk prediction equations is far from universal in the United States, and physicians often simply count risk factors to characterize overall risk.

As reviewed elsewhere,^[@r03],[@r04]^ some scientists have criticized the Framingham 10-year CHD risk estimation for (1) its focus on 10-year CHD risk rather than lifetime risk, (2) the strong contribution of age, which is not modifiable, to CHD prediction, (3) the uncertain generalizability of Framingham risk estimation to other populations, which seems to have been solved by population-specific recalibration,^[@r12]^ (4) a focus on CHD, rather than total CVD, which the Framingham investigators recently resolved with CVD risk equations,^[@r13]^ and (5) the suboptimal accuracy of risk prediction based on the limited set of classical risk factors. However, this concern that classical risk factors are insufficiently predictive is misguided and may have been perpetuated by a long-held belief that classical risk factors explained no more than 50% of CHD occurrence. Recent evidence based on population attributable risk calculations suggests that, in fact, 75% to 85% of CHD in the United States can be prevented by avoiding classical risk factors.^[@r02]^

3. WHICH NOVEL RISK FACTORS MIGHT IMPROVE CARDIOVASCULAR DISEASE PREDICTION?
============================================================================

Even though the classical risk factors for CVD are most important, cardiovascular epidemiologists have remained interested in identifying potential novel risk factors (Table [1](#tbl01){ref-type="table"}). Identification of such factors could help clarify CVD pathophysiology, offer targets for intervention, or lead to improved risk stratification beyond that allowed by the Framingham equations. As Greenland pointed out,^[@r14]^ novel risk factors or biomarkers may be most useful for risk prediction and preventive decision making among patients at "intermediate" Framingham 10-year CHD risk. In contrast, novel risk factor measurement is clinically less useful in high- and low-risk patients. That is, patients at high risk of CHD (as determined using classical risk factors) require intervention regardless of the levels of novel biomarkers, and classically low-risk patients may need no intervention, even if novel biomarkers are elevated.

###### Examples of novel biomarkers of potential interest in cardiovascular disease risk prediction

  ---------------------------------------------------------- ----------------------------------------------------------------
  ***Novel blood and urine markers***                         

   Lipid-related markers                                     Apolipoprotein A1

  Apolipoprotein B100                                        

  Lipoprotein-associated phospholipase A2 (LpPLA~2~)         

  Lipoprotein(a)                                             

                                                             

   Renal function markers                                    Creatinine

  Cystatin-C                                                 

                                                             

   Metabolic markers                                         Adiponectin

  Leptin                                                     

  Insulin                                                    

  Glycosylated hemoglobin (HbA~1~C)                          

                                                             

   Coagulation markers                                       Fibrinogen

  D-dimer                                                    

                                                             

   Markers of vascular function\                             (N-terminal pro) B-type natriuretic peptide
   and neurohumoral activity                                 

  Mid-regional pro-adrenomedullin                            

  Microalbuminuria                                           

                                                             

   Inflammatory markers                                      C-reactive protein (CRP)

  Interleukin-6 (IL-6)                                       

                                                             

   Markers of oxidative stress\                              Homocysteine
   and antioxidants                                          

  Myeloperoxidase                                            

                                                             

   Necrosis markers                                          Troponin I or T

                                                             

  ***Atherosclerosis markers***                               

   Structural                                                Carotid intima-media thickness (IMT) and plaque\
                                                             measured by ultrasound

  Aortic and carotid plaque detected by MRI                  

  Coronary calcium (CAC) score measured by CT                

  Ankle brachial index                                       

  Pulse wave velocity                                        

  Brachial vasoreactivity measured by ultrasound             

                                                             

   Functional                                                Vascular compliance measured by radial tonometry

  Microvascular reactivity measured by fingertip tonometry   

                                                             

  ***Genetic markers***                                      Candidate or discovered single-nucleotide polymorphisms (SNPs)
  ---------------------------------------------------------- ----------------------------------------------------------------

Methods of determining whether a new CVD biomarker adds to risk prediction in epidemiologic cohort studies have received much attention recently. It is not enough to show a novel causal or noncausal biomarker is "independently associated" with CHD. A novel biomarker must add incrementally to CVD prediction equations beyond the classical risk factors, in terms of model performance, discrimination, and calibration and event reclassification^[@r15]--[@r19]^ (Table [2](#tbl02){ref-type="table"}). Thus, the addition of a novel risk factor to an existing CVD risk prediction model should improve the C statistic, and the net reclassification index (NRI) should be sizable. (The C statistic is the area under the receiver operating characteristic \[ROC\] curve and is a measure that discriminates between those who developed disease and those who did not, based on ranks. The NRI for adding a novel risk factor to a prediction model is the net increase versus decrease in risk factor categories among those who developed disease, minus that among those who did not develop disease.) A novel biomarker must have a high risk ratio to contribute incrementally to the very good CHD prediction afforded by classical risk factors.^[@r20]^ Thus, to date, few novel biomarkers of CHD risk have been widely adopted for clinical use in the United States.

###### Some measures of performance for prediction models

  ---------------------------------------------------------------------------------------------
  Aspect                Measure                            Visualization
  --------------------- ---------------------------------- ------------------------------------
  Overall performance   *R*^2^, Brier                      Validation graph

  Discrimination        C statistic                        Receiver operating characteristic\
                                                           (ROC) curve

  Calibration           Calibration slope                  Calibration or validation graph

                        Hosmer-Lemeshow test                

  Reclassification      Reclassification table             Cross-table or scatterplot

                        Net reclassification index (NRI)    

                        Integrated discrimination\         Box plots for 2 models\
                        index (IDI)                        (1 with and 1 without a marker)
  ---------------------------------------------------------------------------------------------

Derived from Reference ^[@r22]^.

Although this report is not a systematic review, Tables [3](#tbl03){ref-type="table"} to [6](#tbl06){ref-type="table"} show examples from recent cohort studies of the extent to which risk prediction models using classical risk factors, like the Framingham model, are improved by the addition of novel biomarkers. As reflected by a change in the C statistic of greater than 0.01 and an NRI of greater than 10%, structural and functional measures of subclinical atherosclerosis, like coronary artery calcium, tend to significantly improve prediction of CHD/CVD risk beyond classical risk factors (Table [3](#tbl03){ref-type="table"}). As shown in Table [4](#tbl04){ref-type="table"}, in most studies, inflammatory and hemostatic blood biomarkers tended to add only modestly beyond classical risk factors (change in C statistic, \<0.01; NRI, \<5%). Two blood biomarkers more specifically related to cardiac dysfunction---high-sensitivity troponin T or I and B-type natriuretic peptide (Table [5](#tbl05){ref-type="table"})---seem to predict CHD somewhat better than inflammatory and hemostatic markers. In contrast, although numerous CVD-related genetic loci have recently been identified,^[@r21]^ genetic markers currently seem to add little to CHD risk prediction models (Table [6](#tbl06){ref-type="table"}).

###### Improvement in CVD/CHD prediction from addition of novel atherosclerosis markers to classical risk factor prediction models

  Study                       Outcome   Markers Added^a^          Δ C statistic^b^   NRI^c^
  --------------------------- --------- ------------------------- ------------------ --------
  MESA^[@r23]^                CHD       CAC                       0.76 → 0.81        0.25
  MESA^[@r24]^                CVD       Small-artery elasticity   0.777 → 0.782      0.11
  Heinz Nixdorf^[@r25]^       CHD       CAC                       0.68 → 0.75        0.22
  Rotterdam^[@r26]^           CHD       CAC                       0.72 → 0.76        0.14
  ARIC^[@r27]^                CHD       Carotid IMT or plaque     0.74 → 0.76        0.10
  ABI Collaboration^[@r42]^   CHD       ABI (men)                 0.646 → 0.655       
                                        ABI (women)               0.605 → 0.658       

^a^CVD, cardiovascular disease; CHD, coronary heart disease; CAC, coronary artery calcium; IMT, intima-media thickness; ABI, ankle brachial index.

^b^Change in C statistic from addition of the novel marker to a classical risk factor model.

^c^Overall net reclassification index (NRI), based on 3 categories^[@r23],[@r25],[@r26]^ or 4 categories^[@r24],[@r27]^ of risk.

###### Improvement in CVD/CHD prediction from addition of SNPs to classical risk factor prediction models

  -------------------------------------------------------------------------------------------
  Study                           Outcome   Markers Added^a^      Δ C Statistic^b^   NRI^c^
  ------------------------------- --------- --------------------- ------------------ --------
  ARIC^[@r39]^                    CHD       9p21 SNP              0.782 → 0.786      0.008

  Scandinavia^[@r40]^             CHD       13 SNP Score          0.87 → 0.87        0.02

  Women's Genome Health^[@r41]^   CVD       101 SNPs\             0.796 → 0.796      0.005
                                            (with FHx in model)                      

  Malmö^[@r32]^                   CVD       9 lipid SNPs          0.80 → 0.80         
  -------------------------------------------------------------------------------------------

^a^CVD, cardiovascular disease; CHD, coronary heart disease; SNP, single-nucleotide polymorphism; FHx, family history.

^b^Change in C statistic from addition of the novel marker to a classical risk factor model.

^c^Overall net reclassification index (NRI), based on 4 categories^[@r39]--[@r41]^ of risk.

###### Improvement in CVD/CHD prediction from addition of novel inflammatory or hemostatic markers to classical risk factor prediction models

  ------------------------------------------------------------------------------------
  Study                       Outcome   Markers Added^a^   Δ C statistic^b^   NRI^c^
  --------------------------- --------- ------------------ ------------------ --------
  Physicians Health^[@r28]^   CVD       CRP, FHx           0.699 → 0.708      0.05

  ARIC^[@r29],[@r30]^         CHD       CRP                0.767 → 0.770       

                                        IL-6               0.773 → 0.783       

                                        D-dimer            0.805 → 0.803       

                                        Fibrinogen (WM)    0.688 → 0.699       

                                        Fibrinogen (WW)    0.793 → 0.795       

  Framingham^[@r31]^          CVD       CRP                0.795 → 0.799      0.06

                              CHD       CRP                0.863 → 0.865      0.12

  Malmö^[@r35]^               CVD       CRP, NT-pro BNP    0.758 → 0.765      0.00

  Women's Health\             CHD       IL-6, D-dimer,\    0.715 → 0.731      0.06
  Initiative^[@r33]^                    FVIII, vWF, hcy                       
  ------------------------------------------------------------------------------------

^a^CVD, cardiovascular disease; CHD, coronary heart disease; FHx, family history; IL-6, interleukin-6; CRP, C-reactive protein; WM, white men; WW, white women; BNP, B-type natriuretic peptide; FVIII, factor VIII; vWF, von Willebrand factor; hcy, homocysteine.

^b^Change in C statistic from addition of the novel marker to a classical risk factor model.

^c^Overall net reclassification index (NRI), based on 3 categories^[@r31],[@r33],[@r35]^ or 4 categories^[@r28]^ of risk.

###### Improvement in CVD/CHD prediction from addition of novel cardiac markers to classical risk factor prediction models

  -----------------------------------------------------------------------------------------
  Study                 Outcome   Markers Added^a^              Δ C Statistic^b^   NRI^c^
  --------------------- --------- ----------------------------- ------------------ --------
  Framingham^[@r34]^    CVD       BNP, albumin/creat            0.76 → 0.77         

  Malmö^[@r35]^         CHD       MR-proADM, NT-pro BNP         0.760 → 0.769      0.05

  ARIC^[@r36]^          CHD       hs-Troponin T                 0.715 → 0.724      0.05

  MORGAM^[@r37]^        CVD       NT-pro BNP, CRP, Troponin I   0.67 → 0.70        0.11

  Uppsala men^[@r38]^   CVD\      Troponin I, NT-pro BNP,\      0.69 → 0.75        0.26
                        death     Cystatin C, CRP                                  
  -----------------------------------------------------------------------------------------

^a^CVD, cardiovascular disease; CHD, coronary heart disease; BNP, B type natriuretic peptide; albumin/creat, urine albumin/creatinine; MR-proADM, mid-regional pro-adrenomedullin; CRP, C-reactive protein.

^b^Change in C statistic from addition of the novel marker to a classical risk factor model.

^c^Overall net reclassification index (NRI), based on 3 categories^[@r35],[@r38]^ or 4 categories^[@r36],[@r37]^ of risk.

4. RECENT US CONSENSUS OPINIONS ON MEASUREMENT OF NOVEL RISK MARKERS
====================================================================

In 2010, a joint task force of the American College of Cardiology and AHA^[@r11]^ issued guidance on which novel risk factors or biomarkers, in addition to classical risk factors, might be currently considered in CHD risk prediction (Table [7](#tbl07){ref-type="table"}). The task force categorized family history as useful and hemoglobin A1c measurement as reasonable in all adults, and they categorized microalbuminuria assessment as reasonable in adults with hypertension or diabetes. With regard to more-novel biomarkers, the task force categorized measurement of C-reactive protein (CRP), lipoprotein-associated phospholipase A2 (LpPLA~2~), coronary calcium, carotid intima-media thickness, and ankle/brachial index to be reasonable for refining risk estimation and making clinical decisions in individuals initially classified as at intermediate CHD risk, using classical risk factors. They did not recommend assessing natriuretic peptides, apolipoproteins, or genetic markers, and they did not evaluate high-sensitivity troponin for its contribution to risk prediction. Additional evidence supporting the use of natriuretic peptides and troponin T or I in risk prediction appeared after the task force met.^[@r36],[@r37]^

###### ACC/AHA^a^ guideline on CVD risk assessment in asymptomatic adults

  --------------------------------------------------------------------------------
                            Useful\   Reasonable\   Reasonable if\   Not\
                            in All    in All        CHD Risk is\     Recommended
                                                    Intermediate     
  ------------------------- --------- ------------- ---------------- -------------
  Family Hx                 ✓                                         

  HbA1c                               ✓                               

  Microalbuminuria                    ✓\*           ✓                 

  CRP                                               ✓                 

  LpPLA~2~                                          ✓                 

  Coronary Calcium                                  ✓                 

  Carotid IMT                                       ✓                 

  Ankle/Brachial Index                              ✓                 

  Brachial Vasoreactivity                                            ✓

  Natriuretic Peptides                                               ✓

  Apolipoproteins                                                    ✓

  Genetic Testing                                                    ✓
  --------------------------------------------------------------------------------

^a^ACC, American College of Cardiology; AHA, American Heart Association; CVD, cardiovascular disease.

\*In patients with hypertension or diabetes.

Source: Reference ^[@r11]^.

5. CONCLUSION
=============

Although enthusiasm for research on novel biomarkers of CVD risk remains high in the United States, only a few such biomarkers have been accepted as clinically useful.
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